120 results on '"Groeneveld, Geert Jan"'
Search Results
2. SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY
3. A Randomized, Double Blind, Placebo-Controlled Study in Patients with Parkinson's Disease with an Alpha-Synuclein Vaccine UB-312
4. Validation of the virtual reality PainCart using diazepam
5. A smartphone- and wearable-based biomarker for the estimation of unipolar depression severity
6. Neurocognitive Effect of Biased µ-Opioid Receptor Agonist Oliceridine, a Utility Function Analysis and Comparison with Morphine
7. Pharmacodynamic Evaluation: Pain Methodologies
8. Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery
9. Machine Learning Techniques for Developing Remotely Monitored Central Nervous System Biomarkers Using Wearable Sensors: A Narrative Literature Review
10. A Phase 1B Trial inGBA1 ‐Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator
11. A first-in-human study in healthy subjects of the safety and pharmacokinetics of CNM-Au8, a suspension of catalytically active gold nanocrystals with remyelinating and neuroprotective properties
12. A Leucine‐Rich Repeat Kinase 2 ( LRRK2 ) Pathway Biomarker Characterization Study in Patients with Parkinson's Disease with and without LRRK2 Mutations and Healthy Controls
13. First‐in‐human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator.
14. The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies. (P8-8.010)
15. Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study
16. Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
17. A Biomarker Study in Patients with GBA1 ‐Parkinson's Disease and Healthy Controls
18. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease
19. Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation
20. A Quantitative‐EEG Assessment of Alpha‐1062, a Novel Pro‐Drug of Galantamine for the Treatment of Mild to Moderate Dementia Associated with Alzheimer’s Disease.
21. A study to evaluate the safety (side effects), how the body processes the treatment (pharmacokinetics), and what the treatment does to the body (pharmacodynamic effects) of single and multiple ascending doses of PRAX-628 in healthy participants
22. Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty
23. Pharmacodynamic Evaluation: Pain Methodologies
24. Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study
25. A Placebo‐Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's Disease
26. Objective Monitoring of Facioscapulohumeral Dystrophy During Clinical Trials Using a Smartphone App and Wearables: Observational Study
27. A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects
28. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
29. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
30. Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study (Preprint)
31. Acute retigabine‐induced effects on myelinated motor axons in amyotrophic lateral sclerosis
32. Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study
33. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients
34. A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
35. Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients
36. ’A study to investigate the effects of two pain killers as a combination treatment for pain
37. Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study
38. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients
39. Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
40. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During MorningOffof AZ ‐009
41. Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation
42. Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI
43. A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Na v 1.8 inhibitor, in healthy adults
44. Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis
45. Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial
46. A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
47. First‐in‐human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR‐324, a dual enkephalinase inhibitor for pain management
48. Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's Disease
49. Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects
50. Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.